ATN-161 ameliorates neuroinflammation and BBB permeability in vascular dementia

March 8, 2024

Vascular dementia accounts for the second most common cause of dementia after Alzheimer’s disease.

BioWorld Science Conferences Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Aug. 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for August 7, 2025.

Chimerix buyout a win for Jazz with FDA nod for rare glioma drug

BioWorld

Jazz Pharmaceuticals plc is prepped and ready for launch following U.S. FDA accelerated approval of dordaviprone as the first systemic therapy for H3 K27M-mutant...

FDA defends use of PFAS in medical devices

BioWorld MedTech

The U.S. FDA has staked out a position on the use of per- and polyfluoroalkyl substances in medical devices, declaring that the evidence offers no reason to...

Results of lithium orotate vs. lithium carbonate on amyloid-β and tau

Lithium could change Alzheimer's care, but not all forms work

BioWorld Science

The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments. Scientists focused on amyloid-β...